Shares of BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) fell 3.9% during trading on Wednesday . The company traded as low as $0.56 and last traded at $0.57. 400,683 shares were traded during mid-day trading, an increase of 21,454% from the average session volume of 1,859 shares. The stock had previously closed at $0.60.
BriaCell Therapeutics Price Performance
The stock’s 50-day moving average price is $0.78 and its 200 day moving average price is $0.99. The firm has a market capitalization of $609,108.00, a PE ratio of -0.16 and a beta of 1.09.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- About the Markup Calculator
- Tesla Investors Continue to Profit From the Trump Trade
- How to Invest in the FAANG Stocks
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- What Does Downgrade Mean in Investing?
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
